Pay in 4 interest-free payments of $6.15 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
** With the SOLIQUA 100/33 Savings Card, patients may be eligible for the $0 CO-PAY offer for the next 12 months
Beyond efficacy: Ensuring safety in peptide therapeutics
Conclusions/interpretation Approximately half of type 2 diabetes patients who had started using GLP-1 receptor agonists or SGLT2 inhibitors had discontinued treatment within 5 years of follow-up
For example, blood sugar levels may rise again after stopping
Factors that may influence the decision include: Individual response to treatment Tolerance to side effects Medical history and underlying conditions Cost and insurance coverage Treatment goals Because both medications are prescription therapies, they should only be used under medical supervision
US$ 19049.50
Sold : Login>>
